HepCInfo Updates

HepCInfo Update 9.7 

Welcome to CATIE's HepCInfo Update 9.7 for March 17 to March 30, 2018. Read on to learn more about new and updated scientific findings in hepatitis C prevention, care, treatment and support.

New and noteworthy

New hepatitis C treatment Vosevi added to the formulary in B.C., Ontario and Quebec

Vosevi, a direct-acting antiviral (DAA) combination has been added to provincial drug plans in B.C., Ontario and Quebec.

Vosevi is a combination of three DAAs, voxilaprevir, a protease inhibitor, velpatasvir, an NS5A inhibitor and sofosbuvir, a nucleotide polymerase inhibitor.

The three drugs are inside one tablet which is taken once per day. Vosevi is taken for 12 weeks.

Vosevi is effective against all hepatitis C genotypes. It is approved in Canada for people over the age of 18 who have previously been treated for hepatitis C with certain DAA treatments but were not cured.

For more information on Vosevi, see the CATIE factsheet, Vosevi.

Being cured of hepatitis C reduces risk of diabetes

People who were cured of hepatitis C were 21% less likely to develop type 2 diabetes than people who were not cured, reported researchers in the Journal of Viral Hepatitis.

The researchers examined data from the Chronic Hepatitis Cohort Study (CHeCS) which includes people with hepatitis B and C from four large U.S. health systems.  

Participants included 5137 people who had received hepatitis C care and treatment between 2006 and 2015.  Most participants were male (60%), white (72%) and the average age was 59 years.

Approximately three-quarters (73%) of participants were treated and cured of hepatitis C. During an average follow up time of 3.7 years there were 530 new cases of type 2 diabetes post-treatment.

After controlling for potential confounders, being cured of hepatitis C reduced the risk of developing type 2 diabetes by 21%.

People who were more likely to develop type 2 diabetes after not being cured from treatment included people with a very high body mass index (greater than 30), people over the age of 60 years, people who had cirrhosis prior to HCV treatment and people of colour.

According to the researchers, “Among a geographically- and racially-diverse cohort of more than 5,000 patients from US healthcare systems, successful hepatitis C treatment was associated with significant reductions in the incidence of type 2 diabetes.” (infohep.org, March 2018)

Straight to the source for new science

Patient Views on Advance Care Planning in Cirrhosis: A Qualitative Analysis, Canadian Journal of Gastroenterology and Hepatology, February 2018